KR20190077124A - 생물학적 활성 분자의 세포내 전달을 위한 작용화 나노입자 - Google Patents

생물학적 활성 분자의 세포내 전달을 위한 작용화 나노입자 Download PDF

Info

Publication number
KR20190077124A
KR20190077124A KR1020197018256A KR20197018256A KR20190077124A KR 20190077124 A KR20190077124 A KR 20190077124A KR 1020197018256 A KR1020197018256 A KR 1020197018256A KR 20197018256 A KR20197018256 A KR 20197018256A KR 20190077124 A KR20190077124 A KR 20190077124A
Authority
KR
South Korea
Prior art keywords
cell
nanoparticles
altering
nanoparticle
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197018256A
Other languages
English (en)
Korean (ko)
Inventor
앤드라닉 앤드류 애프리키언
킬리언 딜
Original Assignee
스템제닉스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스템제닉스 인코포레이티드 filed Critical 스템제닉스 인코포레이티드
Publication of KR20190077124A publication Critical patent/KR20190077124A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
    • B60R22/00—Safety belts or body harnesses in vehicles
    • B60R22/34—Belt retractors, e.g. reels
    • B60R22/341—Belt retractors, e.g. reels comprising energy-absorbing means
    • B60R22/3413—Belt retractors, e.g. reels comprising energy-absorbing means operating between belt reel and retractor frame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
    • B60R22/00—Safety belts or body harnesses in vehicles
    • B60R22/28—Safety belts or body harnesses in vehicles incorporating energy-absorbing devices
    • B60R2022/286—Safety belts or body harnesses in vehicles incorporating energy-absorbing devices using deformation of material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
    • B60R22/00—Safety belts or body harnesses in vehicles
    • B60R22/28—Safety belts or body harnesses in vehicles incorporating energy-absorbing devices
    • B60R2022/289—Energy-absorption curves
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mechanical Engineering (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
KR1020197018256A 2011-10-21 2012-10-22 생물학적 활성 분자의 세포내 전달을 위한 작용화 나노입자 Ceased KR20190077124A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161550213P 2011-10-21 2011-10-21
US61/550,213 2011-10-21
PCT/US2012/061391 WO2013059831A1 (en) 2011-10-21 2012-10-22 Functionalized nanoparticles for intracellular delivery of biologically active molecules

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR20147010620A Division KR20150001711A (ko) 2011-10-21 2012-10-22 생물학적 활성 분자의 세포내 전달을 위한 작용화 나노입자

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207010401A Division KR20200040924A (ko) 2011-10-21 2012-10-22 생물학적 활성 분자의 세포내 전달을 위한 작용화 나노입자

Publications (1)

Publication Number Publication Date
KR20190077124A true KR20190077124A (ko) 2019-07-02

Family

ID=48141479

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197018256A Ceased KR20190077124A (ko) 2011-10-21 2012-10-22 생물학적 활성 분자의 세포내 전달을 위한 작용화 나노입자
KR20147010620A Ceased KR20150001711A (ko) 2011-10-21 2012-10-22 생물학적 활성 분자의 세포내 전달을 위한 작용화 나노입자
KR1020207010401A Ceased KR20200040924A (ko) 2011-10-21 2012-10-22 생물학적 활성 분자의 세포내 전달을 위한 작용화 나노입자

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR20147010620A Ceased KR20150001711A (ko) 2011-10-21 2012-10-22 생물학적 활성 분자의 세포내 전달을 위한 작용화 나노입자
KR1020207010401A Ceased KR20200040924A (ko) 2011-10-21 2012-10-22 생물학적 활성 분자의 세포내 전달을 위한 작용화 나노입자

Country Status (14)

Country Link
US (1) US9675708B2 (https=)
EP (2) EP3400956A1 (https=)
JP (3) JP2014532628A (https=)
KR (3) KR20190077124A (https=)
CN (2) CN104094119A (https=)
AU (3) AU2012325723A1 (https=)
BR (1) BR112014009753B1 (https=)
CA (2) CA2938661A1 (https=)
HK (1) HK1201089A1 (https=)
IN (1) IN2014DN03224A (https=)
MX (3) MX367656B (https=)
RU (2) RU2018135567A (https=)
SG (2) SG11201401658SA (https=)
WO (1) WO2013059831A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2938661A1 (en) * 2011-10-21 2013-04-25 Stemgenics, Inc Functionalized nanoparticles for intracellular delivery of biologically active molecules
US9687519B2 (en) 2013-03-01 2017-06-27 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
ES2755134T3 (es) 2013-03-01 2020-04-21 Stealth Biotherapeutics Corp Métodos para el tratamiento de enfermedad mitocondrial
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
WO2015027243A2 (en) * 2013-08-23 2015-02-26 Rutgers The State University Of New Jersey Biologically active synthetic nanoparticle constructs and mehtods of use therof
US11306326B2 (en) 2013-08-23 2022-04-19 Rutgers, The State University Of New Jersey Biologically active synthetic nanoparticle constructs and methods of use thereof
EP3105318A1 (en) * 2014-02-10 2016-12-21 Nvigen, Inc. Cell modulation nanocomposition, and methods of use
CN105440112A (zh) * 2015-12-07 2016-03-30 国家纳米科学中心 多肽-白蛋白偶联药物、其制备方法及应用
WO2017210666A2 (en) * 2016-06-03 2017-12-07 Stemgenics, Inc. Functionalized nanoparticles for the intracellular delivery of biologically active molecules and methods for their manufacture and use
EP3463383A4 (en) * 2016-06-03 2020-02-12 Stemgenics, Inc. DIRECT REPROGRAMMING OF A HUMAN SOMATIC CELL IN A DIFFERENTIATED (PREDETERMINED) CELL SELECTED WITH FUNCTIONALIZED NANOPARTICLES
CA3039924A1 (en) * 2016-10-11 2018-04-19 Stemgenics, Inc. Nanoparticles functionalized with gene editing tools and related methods
US11491114B2 (en) 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
US11065345B2 (en) * 2017-01-04 2021-07-20 Nanotics, Llc Methods for assembling scavenging particles
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
US11701433B2 (en) 2017-06-05 2023-07-18 The Regents Of The University Of Michigan Complexes for delivery of antigenic peptides
WO2019099685A1 (en) 2017-11-15 2019-05-23 Rutgers, The State University Of New Jersey Biodegradable hybrid inorganic nanoscaffolding materials and methods of use and manufacture thereof
CN108287235B (zh) * 2018-02-07 2021-03-09 常州天地人和生物科技有限公司 一种高效、稳定的磁性免疫微球的制备和应用
US20200326325A1 (en) 2019-04-12 2020-10-15 Lisa Diamond Nanosensor chip with compound nanopores
CN112111042B (zh) * 2019-06-21 2024-04-05 康码（上海）生物科技有限公司 一种生物磁性微球及其制备方法和使用方法
CN110642876A (zh) * 2019-10-10 2020-01-03 南京市口腔医院 半胱氨酸修饰金纳米颗粒和制备方法、应用及促进骨组织再生产品
CN112472685B (zh) * 2020-12-10 2023-03-24 哈尔滨工业大学 一种杂化中性粒细胞机器人的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2384429A1 (en) * 1999-09-14 2001-03-22 Michael K. Bahr Magnetic nanoparticles having biochemical activity, method for the production thereof and their use
US7329638B2 (en) * 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
JP4901471B2 (ja) * 2004-02-19 2012-03-21 国立大学法人京都大学 体細胞核初期化物質のスクリーニング方法
CN101389314A (zh) 2005-03-14 2009-03-18 得克萨斯大学体系董事会 生物活性fus1肽和纳米颗粒-多肽复合物
AU2006339072A1 (en) * 2005-03-14 2007-10-25 Board Of Regents Of The University Of Texas System Bioactive FUS1 peptides and nanoparticle-polypeptide complexes
CN102016814B (zh) * 2005-06-17 2013-10-23 北卡罗来纳大学查珀尔希尔分校 纳米粒子制备方法、系统及材料
WO2008073856A2 (en) * 2006-12-08 2008-06-19 Massachusetts Institute Of Technology Delivery of nanoparticles and/or agents to cells
CA2672998C (en) 2007-01-02 2013-08-06 University Of Central Florida Research Foundation, Inc. Methods and materials for stimulating proliferation of stem cells
KR100925689B1 (ko) * 2007-07-25 2009-11-10 한국생명공학연구원 항체와 나노입자를 세포 내로 동시에 전달할 수 있는다기능성 단백질
EP2203059A4 (en) 2007-09-10 2010-11-10 Merck Sharp & Dohme METHOD FOR TREATING UNAUTHORIZED HEAVY NEUTROPENIA
KR100951719B1 (ko) * 2007-10-02 2010-04-07 재단법인서울대학교산학협력재단 세포투과성 펩타이드와 형광표지 자성나노입자의 복합체 및그 용도
US20110190729A1 (en) * 2007-11-30 2011-08-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving sox2 protein
JP2011514160A (ja) 2008-02-21 2011-05-06 バーナム インスティテュート フォー メディカル リサーチ Ｃ末端エレメントを有するペプチドおよびタンパク質に関する方法および組成物
EP2641911A3 (en) * 2008-12-23 2014-01-01 Vivoscript, Inc. Compositions and methods for re-programming cells without genetic modification
TWI576432B (zh) * 2009-04-07 2017-04-01 陶氏農業科學公司 序列特異性核酸酶之奈米粒子媒介式遞送技術
CA2938661A1 (en) * 2011-10-21 2013-04-25 Stemgenics, Inc Functionalized nanoparticles for intracellular delivery of biologically active molecules

Also Published As

Publication number Publication date
MX367656B (es) 2019-08-29
MX2014004778A (es) 2014-10-17
BR112014009753A2 (pt) 2017-04-25
IN2014DN03224A (https=) 2015-05-22
EP2769217A1 (en) 2014-08-27
AU2012325723A1 (en) 2014-05-15
KR20150001711A (ko) 2015-01-06
HK1201089A1 (en) 2015-08-21
CA2853128A1 (en) 2013-04-25
RU2018135567A (ru) 2018-11-15
AU2018203848A1 (en) 2018-06-21
BR112014009753B1 (pt) 2020-09-15
JP6560302B2 (ja) 2019-08-14
US9675708B2 (en) 2017-06-13
SG11201401658SA (en) 2014-07-30
JP2017165781A (ja) 2017-09-21
US20140342004A1 (en) 2014-11-20
CA2938661A1 (en) 2013-04-25
AU2020223737A1 (en) 2020-09-17
EP3400956A1 (en) 2018-11-14
JP2018184485A (ja) 2018-11-22
KR20200040924A (ko) 2020-04-20
RU2014120465A (ru) 2015-11-27
MX2018010696A (es) 2020-09-02
WO2013059831A1 (en) 2013-04-25
SG10201601746TA (en) 2016-04-28
JP2014532628A (ja) 2014-12-08
CN106822868A (zh) 2017-06-13
EP2769217A4 (en) 2015-06-03
CA2853128C (en) 2016-09-27
CN104094119A (zh) 2014-10-08

Similar Documents

Publication Publication Date Title
KR20190077124A (ko) 생물학적 활성 분자의 세포내 전달을 위한 작용화 나노입자
US10179194B2 (en) Self-assembling peptides, peptidomimetics and peptidic conjugates as building blocks for biofabrication and printing
EP3395327B1 (en) Non-covalently assembled conductive hydrogel
JP2020519605A (ja) 組織エンジニアリングおよびバイオプリンティングにおける使用のためのゲルを形成し得るペプチド
KR20160088431A (ko) 나노섬유 하이드로겔로 자기 조립되는 신규한 초단 소수성 펩티드 및 그 용도
Li et al. Nanoparticle-mediated conversion of primary human astrocytes into neurons and oligodendrocytes
CN119040255B (zh) 基于动态水凝胶的外泌体的制备方法及递送体系
CN119039458B (zh) 兼具靶向和渗透作用的多功能融合肽及其应用
EP3638313B1 (en) Non-covalently assembled biomatrix layer
HK1236412A1 (en) Functionalized nanoparticles for intracellular delivery of biologically active molecules
HK1236412A (en) Functionalized nanoparticles for intracellular delivery of biologically active molecules
KR20190028665A (ko) 기능화된 나노입자(functionalized nanoparticles)를 사용하여 선택된(예정된) 분화된 세포에 대한 사람 체세포의 직접적인 재프로그래밍
US11298424B2 (en) Non-ionic and thermoresponsive diblock copolypeptide hydrogels for delivery of molecules and cells
US20260108612A1 (en) Beta-peptides and beta-peptide hydrogels
Sun et al. Nano-primed reprogrammed neurons suppress the glial scar and facilitate axonal regeneration after spinal cord injury
HK40078277A (en) Direct reprogramming of a human somatic cell to a selected (predetermined) differentiated cell with functionalized nanoparticles
HK1228419A1 (en) Novel ultrashort hydrophobic peptides that self-assemble into nanofibrous hydrogels and their uses

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190624

Application number text: 1020147010620

Filing date: 20140421

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190704

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200109

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190704

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I